迷幻药通过激活细胞内5-HT2A受体促进神经可塑性
Maxemiliano V Vargas1,2, Lee E Dunlap2,3, Chunyang Dong4
1Neuroscience Graduate Program, University of California, Davis, Davis, CA 95618, USA.
概括
心理药物通过激活细胞内5-三胺 (氨酸) 2A受体 (5-HT2ARs) 来促进大脑的可塑性,与氨酸本身不同. 这一发现强调了细胞内5-HT2ARs作为神经精神疾病的新疗法标.
科学领域:
- 神经科学
- 药理学
- 分子生物学
背景情况:
- 皮质树突脊柱密度下降是神经精神疾病的标志.
- 心理药物的治疗效果与促进皮质神经元生长和可塑性有关.
- 对这种可塑性来说,5- 三胺 (胺) 2A受体 (5-HT2ARs) 的激活至关重要.
研究的目的:
- 为了研究精神药物促进神经可塑性的机制.
- 确定为什么只有某些5-HT2AR激动剂会诱导神经可塑性.
- 阐明受体位置在5-HT2AR信号传递中的作用.
主要方法:
- 使用分子和遗传工具.
- 研究了细胞内5-HT2AR信号通路.
- 对比了迷幻激动剂对5-HT2ARs的影响.
主要成果:
- 证明细胞内5-HT2ARs调解了迷幻药的塑性促进作用.
- 表明血清素没有类似的可塑性机制,解释了它的不同作用.
- 突出了受体位置偏差在5-HT2AR信号传递中的意义.
结论:
- 细胞内5-HT2ARs是迷幻诱导皮质可塑性的关键媒介.
- 已确定细胞内5-HT2AR作为神经精神疾病的潜在治疗点.
- 表明血清素可能不是皮层中细胞内5-HT2AR的内源配体.
相关概念视频
CNS Stimulants: Psychedelic Agents
207
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
207
Neuroplasticity
648
Neuroplasticity reflects the brain's remarkable capacity to adapt and evolve, responding dynamically to learning, experiences, or injury by reorganizing its neural circuitry. This reorganization involves creating new neural connections and refining old ones through a series of biological processes that contribute to the brain's lifelong development and adaptability.
648
Hallucinogens and Psychedelics
231
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
231
Drugs Affecting Neurotransmitter Synthesis
1.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.5K
Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K
Neurochemical Transmission: Sites of Drug Action
2.5K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
2.5K


